Hot Stocks: Summer Infant, Peregrine Pharmaceuticals, Spectrum Pharmaceuticals, Velti

Lakeway, NY -- (SBWIRE) -- 03/13/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Summer Infant, Inc. (NASDAQ:SUMR) surged up 8.62% to $2.52 on a traded volume of 49k shares. The company reported fourth quarter results. Net revenues increased 6% to $58.5 million. The increase in revenue was primarily driven by higher sales of furniture, safety, plays and monitors products. Gross profit for the fourth quarter of 2012 was $18.3 million from $19.5 million in the fourth quarter of 2011. The net loss was $1.5 million or $0.09 per share in the fourth quarter of 2012, compared to net loss of $0.4 million, or $0.02 per share in the fourth quarter of 2011.

Is SUMR a Strong After The recent price Movement? Let’s Find out Here

Peregrine Pharmaceuticals (NASDAQ:PPHM) increased 3.80% to $1.64 on a traded volume of 65k shares. The Company reported third quarter loss of $4.9 million or 4 cents per share from loss of $11.1 million or 13 cents per share in the prior year period. Revenue grew to $7 million from $3.3 million over the three months ended January 31. Analysts forecast a loss of 7 cents per share on $4.1 million in revenue, according to FactSet.

Is PPHM a Strong Buying Opportunity After The Recent Slump? Find out Here

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) slipped 35.80% to $7.98. The Company commented on anticipated first quarter performance and updated its 2013 outlook for the Company. Spectrum Pharmaceuticals anticipates a change in ordering patterns of FUSILEV following the recent stabilization of the folate analog market. The Company now expects that FUSILEV sales will be approximately $10 to $15 million for the first quarter of the year, and approximately $80 to $90 million for the 2013 fiscal year.

Is SPPI Signaling a Buy Signal After The recent Volatility? Let’s Find out Here

Velti Plc. (NASDAQ:VELT) moved down 26.69% to $2.28. The Company released fourth quarter results. Revenue increased 12% to $97.5 million. Revenue less 3rd party costs was $66.6 million, a decrease of 2% compared with revenue less 3rd party costs from Q4 2011. Adjusted EBITDA was $25.1 million compared with $43.1 million in Q4 2011. GAAP net loss attributable to Velti was $5.2 million and diluted EPS of $(0.08) compared with net income of $25.0 million and EPS of $0.40 for Q4 2011. Adjusted net income was $26.0 million and adjusted diluted EPS of $0.39 compared with adjusted net income of $37.3 million and adjusted diluted EPS of $0.59 for Q4 2011.

Is VELT a Strong Buying Opportunity After The Recent Gain? Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.